Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

By O. Chinot, Wolfgang Wick, W. Mason, R. Henriksson, F. Saran, R. Nishikawa, A. Carpentier, K. Hoang-Xuan, P. Kavan, D. Cernea and 4 more. New England Journal of Medicine, 2014

2,250 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/28d2bf30178f9ebee51bdc8c6cce5eb45127de36

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller
2. J. Joyce
3. D. Quail

In Molecular Biology

1. A. Adamis
2. J. Joyce
3. N. Ferrara
4. P. Wen
5. D. Quail
6. Rakesh K. Jain
7. Peter Carmeliet
8. R. Apte

In Pulmonary and Respiratory Medicine

1. N. Ferrara

Citations in the corpus

• The microenvironmental landscape of brain tumors (2017, background): “These findings were in part recapitulated by another Phase III study in glioblastoma, which reported no improvement in overall survival and increased incidence of adverse events with the addition of bevacizumab to radiotherapy-temozolomide treatment (Chinot et al., 2014).”
• Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017, background): “0 (70-100) 90-100 308 (66) 149 (65) ≤80 154 (33) 74 (32) Missing 4 (1) 6 (3) Sex Men 316 (68) 157 (69) Women 150 (32) 72 (31) Region United States 221 (47) 118 (52) Outside the United States 245 (53) 111 (48) Race/ethnicity White 416 (89) 201 (88) African American 3 (1) 1 (<1) Asian 27 (6) 19 (8) Hi”
• Glioma Subclassifications and Their Clinical Significance (2017, background): “tients with GBM [85], but a post-hoc analysis did identify a potential survival increase (17.”
• Current Challenges and Opportunities in Treating Glioblastoma (2018, background): “…trial, conducted on 921 patients with newly diagnosed GBM, resulted in no overall survival benefit in bevacizumab-treated versus placebo-treated patients (median overall survival of 16.8 months for bevacizumab-treated patients and 16.7 months for placebo-treated patients) (Chinot et al., 2014).”
• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015, background): “For example, 3 large phase 3 trials were completed, based on promising phase 3 data, which failed to significantly extend OS.5,6,16 These failures highlight the need to optimize the use of imaging as a surrogate tool to better understand the response to novel therapeutics.”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “80) , involving newly diagnosed GBM patients, PFS, but not OS, were improved with the combination of bevacizumab with radiotherapy and temozolomide compared with radiotherapy and temozolomide alone 87,88 .”